《大行報告》瑞銀首予鷹瞳科技(02251.HK)「買入」評級 目標價75.2元
瑞銀日前(12月17日)發表報告,首予鷹瞳科技(02251.HK)「買入」評級,目標價75.2元。
瑞銀指,鷹瞳科技成立於2015年,是一家人工智能公司,專注於基於視網膜的早期檢測、診斷和健康風險評估解決方案,認為公司是AI視網膜影像領域的領導者,雖然該領域仍處於早期階段,但有可能在2025年發展至47億人民幣的市場。
瑞銀指,投資者對鷹瞳科技的擔憂是行業的市場規模和競爭力,相信公司可以在未來12個月內逐步達到關鍵里程碑,證明增長潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.